JAK-IN-14

Cat. No.:	HY-139807				
CAS No.:	1973485-06-1				
Molecular Formula:	C ₁₉ H ₁₅ FN ₄ O				
Molecular Weight:	334.35				
Target:	JAK				
Pathway:	Epigenetics; JAK/STAT Signaling; Stem Cell/Wnt				
Storage:	Powder	-20°C	3 years		
		4°C	2 years		
	In solvent	-80°C	6 months		
		-20°C	1 month		

SOLVENT & SOLUBILITY

In Vitro	DMSO : 10.5 mg/mL (31.40 mM; ultrasonic and warming and heat to 60°C)						
Preparing Stock Solution		Solvent Mass Concentration	1 mg	5 mg	10 mg		
	Preparing Stock Solutions	1 mM	2.9909 mL	14.9544 mL	29.9088 mL		
		5 mM	0.5982 mL	2.9909 mL	5.9818 mL		
		10 mM	0.2991 mL	1.4954 mL	2.9909 mL		
	Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 1.05 mg/mL (3.14 mM); Clear solution						
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 1.05 mg/mL (3.14 mM); Suspended solution; Need ultrasonic						
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 1.05 mg/mL (3.14 mM); Clear solution						

BIOLOGICAL ACTIV	ТТ
Description	JAK-IN-14 is a potent and selective JAK1 inhibitor, with an IC ₅₀ of <5 μM. JAK-IN-14 is >8-fold more selective for JAK1 tha JAK2 and JAK3 (Patent WO2016119700A1, compound 16) ^[1] .

REFERENCES

Product Data Sheet

N

NH



[1]. Jin Li, et al. Substituted imidazo [1, 2-a] pyridin-2-ylamine compounds, and pharmaceutical compositions and methods of use thereof. WO2016119700A1.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA